<DOC>
	<DOCNO>NCT00196963</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity , safety reactogenicity one dose four different formulation MenACWY conjugate vaccine give healthy subject age 15-19 year . The selection best formulation base data obtain one month vaccine dose .</brief_summary>
	<brief_title>Evaluate 4 Different Formulations Meningococcal Serogroups A , C , W-135 , Y Conjugate Vaccine When Given 1 Dose Healthy Subjects Aged 15-19 Yrs</brief_title>
	<detailed_description>3 formulation GSK 's MenACWY conjugate vaccine administer double-blind manner , 4th one single-blinded . Administration candidate vaccine active control ( Mencevax™ ACWY ) do open manner . Subjects receive one vaccine dose ( GSK 's MenACWY conjugate vaccine Mencevax™ ACWY vaccine ) , 2 blood sample take , one month vaccination .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : Healthy male female , include , 15 19 year age time vaccination . Written inform consent obtain . Subject previously complete routine childhood vaccination best his/her knowledge his/her parents'/guardians ' knowledge . Female subject nonchildbearing potential , abstinent , use adequate contraception . Exclusion criterion : Previous vaccination OR history OR exposure within previous 12 month meningococcal serogroup A , C , W135 Y disease . Administration tetanus vaccine within 6 month study vaccination . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . History neurologic disorder seizure . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>